EUVIMEDOpdag EUVIMED
Crossref

Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death

Xikuang Yao iD, Changrui Sun, Fei Xiong, Weina Zhang iD, Wenjing Yao, Yinghui Xu, Wenpei Fan iD, Fengwei Huo iD

ACS Applied Materials & Interfaces · 2024

DOI: 10.1021/acsami.4c00166 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2024. Written by Xikuang Yao and 7 co-authors. Institution: School of Flexible Electronics (Future Technologies) and Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), Nanjing 211816…. Major MEDLINE topics: Polyethylene Glycols, Neoplasms, Peptides. Cited 23 times so far (Crossref); 26 references. Funded by: China Pharmaceutical University, Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Nanomedicine-enhanced immunogenic cell death (ICD) has attracted considerable attention for its great potential in cancer treatment. Even though polyethylene glycol (PEG) is widely recognized as the gold standard for surface modification of nanomedicines, some shortcomings associated with this PEGylation, such as hindered cell endocytosis and accelerated blood clearance phenomenon, have been revealed in recent years. Notably, polysarcosine (PSar) as a highly biocompatible polymer can be finely synthesized by mild ring-opening polymerization (ROP) of sarcosine N-carboxyanhydrides (Sar-NCAs) and exhibit great potential as an alternative to PEG. In this article, PSar-b-polycamptothecin block copolymers are synthesized by sequential ROP of camptothecin-based NCAs (CPT-NCAs) and Sar-NCAs. Then, the detailed and systematic comparison between PEGylation and PSarylation against the 4T1 tumor model indicates that PSar decoration can facilitate the cell endocytosis, greatly enhancing the ICD effects and antitumor efficacy. Therefore, it is believed that this well-developed PSarylation technique will achieve effective and precise cancer treatment in the near future.

Subjects

MeSH terms (MEDLINE)

Polyethylene GlycolsNeoplasmsPeptidesHumansSarcosineCamptothecinImmunogenic Cell DeathPolymers

Author keywords

PEG alternativecamptothecinimmunogenic cell deathnanomedicinepolysarcosine

Substances

polysarcosinePolyethylene GlycolsSarcosineCamptothecinPolymersPeptides

Authors and institutions

  • School of Flexible Electronics (Future Technologies) and Institute of Advanced Materials (IAM), Nanjing Tech University (NanjingTech), Nanjing 211816, China.
  • State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Advanced Pharmaceuticals and Biomaterials, China Pharmaceutical University, Nanjing 211198, China.

ORCID profiles: Xikuang Yao, Weina Zhang, Wenpei Fan, Fengwei Huo

Funding

  • China Pharmaceutical University
  • Natural Science Foundation of Jiangsu Province
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Natural Science Foundation of the Jiangsu Higher Education Institutions

Cite

APA

Yao, X., Sun, C., Xiong, F., Zhang, W., Yao, W., Xu, Y., Fan, W., & Huo, F. (2024). Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.4c00166

Vancouver

Yao X, Sun C, Xiong F, Zhang W, Yao W, Xu Y, et al. Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death. ACS Applied Materials & Interfaces. 2024. doi:10.1021/acsami.4c00166

BibTeX
@article{Yao2024,
  author = {Yao, Xikuang and Sun, Changrui and Xiong, Fei and Zhang, Weina and Yao, Wenjing and Xu, Yinghui and Fan, Wenpei and Huo, Fengwei},
  title = {Polysarcosine as PEG Alternative for Enhanced Camptothecin-Induced Cancer Immunogenic Cell Death},
  journal = {ACS Applied Materials & Interfaces},
  year = {2024},
  doi = {10.1021/acsami.4c00166}
}
Start for free →